Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest.

[1]  S. Westaby.  Aprotinin in perspective. , 1993, The Annals of thoracic surgery.

[2]  F. Loop,et al.  Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. , 1992, The Annals of thoracic surgery.

[3]  A. Griesmacher,et al.  Aprotinin decreases release of 6-keto-prostaglandin F1 alpha and increases release of thromboxane B2 in cultured human umbilical vein endothelial cells. , 1992, The Journal of thoracic and cardiovascular surgery.

[4]  M. Yacoub,et al.  Guidelines for monitoring heparin by the activated clotting time when aprotinin is used during cardiopulmonary bypass. , 1992, The Journal of thoracic and cardiovascular surgery.

[5]  W. Vanoeveren,et al.  Anticoagulation policy during use of aprotinin in cardiopulmonary bypass. , 1992 .

[6]  W. Dietrich,et al.  High-dose aprotinin in cardiac surgery: three years' experience in 1,784 patients. , 1992, Journal of cardiothoracic and vascular anesthesia.

[7]  D. Royston.  High-dose aprotinin therapy: a review of the first five years' experience. , 1992, Journal of cardiothoracic and vascular anesthesia.

[8]  L. V. von Segesser,et al.  Low-dose aprotinin also allows reduction of blood loss after cardiopulmonary bypass. , 1991, The Journal of thoracic and cardiovascular surgery.

[9]  R. Colman,et al.  Invited letter concerning: aprotinin. , 1991, The Journal of thoracic and cardiovascular surgery.

[10]  W. van Oeveren,et al.  Aprotinin reduces intraoperative and postoperative blood loss in membrane oxygenator cardiopulmonary bypass. , 1991, The Annals of thoracic surgery.

[11]  H. Teufelsbauer,et al.  Effect of intraoperative aprotinin administration on postoperative bleeding in patients undergoing cardiopulmonary bypass operation. , 1991, The Journal of thoracic and cardiovascular surgery.

[12]  J. E. Doran,et al.  Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass. , 1991, The Journal of thoracic and cardiovascular surgery.

[13]  W. van Oeveren,et al.  Increased anticoagulation during cardiopulmonary bypass by aprotinin. , 1990, The Journal of thoracic and cardiovascular surgery.

[14]  W. van Oeveren,et al.  Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. , 1990, The Journal of thoracic and cardiovascular surgery.

[15]  J. Griffin,et al.  Aprotinin (trasylol) is a competitive inhibitor of activated protein C. , 1989, Thrombosis research.

[16]  T. Emerson.  Pharmacology of Aprotinin and Efficacy During Cardiopulmonary Bypass , 1989 .

[17]  D. Cosgrove,et al.  Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). , 1989, The Journal of thoracic and cardiovascular surgery.

[18]  W. van Oeveren,et al.  Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. , 1987, The Annals of thoracic surgery.

[19]  D. Lane,et al.  The neutralisation of heparin by Trasylol. , 1980, Thrombosis research.

[20]  J. Salaman,et al.  TRASYLOL (APROTININ) AND KIDNEY PRESERVATION , 1978, Transplantation.

[21]  H. Nagaoka,et al.  Effects of aprotinin on prostaglandin metabolism and platelet function in open heart surgery. , 1991, The Journal of cardiovascular surgery.

[22]  Fischer Jh,et al.  Aprotinin (Trasylol) protection--unsuitable for hypothermic kidney preservation. , 1984 .